anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
DepoCyt is a sustained-release formulation of the chemotherapy drug, cytarabine (Ara-C), which is used for the treatment of patients with lymphomatous or leukemic meningitis, a complication of lymphoma/leukemia that is characterized by the spread of cancer to the central nervous system.

DepoCyt is introduced into the spinal fluid, through a needle inserted into the spinal canal or through a reservoir placed under the scalp by a neurosurgeon. DepoCyt will be given every two weeks i.e. week 1 and week 3 initially. After the second dose, a lumbar puncture will be done to check the spinal fluid for cancer cells. If there has been a good response, DepoCyt will be given every 14 days for 6 doses i.e., weeks 5, 7, 9, 11, 13, 15 and then every 28 days for six doses i.e., weeks 19, 23, 27, 31, 35, and 39. Blood tests and lumbar punctures will be done throughout the study.
The invention discloses an extraction method of salvianolic acid B and hydroxy safflor yellow A as well as a preparation method of danhong for injection, and relates to the extraction method of the salvianolic acid and the hydroxy safflor yellow as well as the preparation method of the danhong preparation. The invention solves the problems that the extraction of the salvianolic acid B and the hydroxy safflor yellow A is not thorough, and the transportation and the storage of the prepared danhong injection are inconvenient. The salvianolic acid B of the invention is extracted according to the following steps: backflow, acidification and adsorption; thus the salvianolic acid B is obtained. The hydroxy safflor yellow A of the invention is extracted according to the following steps: boil out, acidification and adsorption; thus the hydroxy safflor yellow A is obtained. The danhong for injection is extracted according to the following steps: compounding ratio and standing, filtrating and lyophylization; thus the danhong for injection of the invention is obtained. The extraction rate of the salvianolic acid B and the hydroxy safflor yellow A of the invention is high, and the transportation and the storage of the prepared danhong injection are convenient.
A method, wireless communication device, and information processing system are provided for monitoring lifestyle activities. The method includes receiving a set of user activity identifiers associated with a set of user activities (804). At least one sensor assigned to each user activity in the set of user activities is identified (1004). At least one user activity context is associated with each user activity in the set of user activities (810). The method also includes monitoring for an occurrence of the at least one user activity context (822). Based on the monitoring, it is determined whether the at least one user activity context has occurred (822). Each sensor (122) assigned to the user activity associated with the at least one user activity context is monitored in response to the at least one user activity context having occurred (1006).
The EM-HEART study is a prospective, multi-centre stepped wedge cluster randomized trial to evaluate the effectiveness of a pragmatic EM program to improve patient-centred and clinical outcomes in older adults with acute CV disease. There will be 256 participants ≥60 years old with acute CV disease enrolled at 6 participating Canadian hospitals. The study will investigate whether EM improves functional status during admission, as compared to usual care, and whether this leads to improved health-related quality of life post-hospitalization. Functional status will be measured with the validated Level of Function Mobility Scale. The primary outcome will be the Short-Form SF-36 physical component scale score at 1-month post-hospitalization. Secondary outcomes include functional status and hospital readmission at 1-month post-hospitalization. Nested cohort studies will explore (1) the relationship between EM, sedentary time, and posthospitalization outcomes and (2) the impact of EM on muscle mass loss and inflammation in older adults with acute CV disease.
A method for recipe standardization has the steps of a user creating a profile having one or more user characteristics, wherein the one or more user characteristics comprises user tolerance. A system prompting user input, wherein the system provides one or more options for recipe creation. The user selecting at least one of the one or more options for recipe creation; the user selecting desired effect of the recipe, wherein the desired effect is selected from one or more scales. The system determining the composition of the recipe. An algorithm creating a threshold, wherein the algorithm accounts for the user characteristics and the desired effect. The algorithm adjusting the amount of one or more of recipe components, wherein the adjusting is based on a deviation of the user characteristics from the threshold. The system generating instruction for recipe preparation.
<P>PROBLEM TO BE SOLVED: To provide an information processing system and an information terminal in which data can be erased to prevent the outflow of personal information or the like when a PC storing data including the personal information are illegally taken out.  <P>SOLUTION: The information processing system comprises an information terminal and a management terminal capable of communicating with the information terminal. The information terminal includes a storage part capable of storing predetermined information and a location information calculation device for calculating its own location information. The management terminal is provided with a means for receiving the location information from the location information calculation device and grasping the moving state of the information terminal. When the unexpected movement of the information terminal is decided, the information processing system makes the information terminal start a data erasing program and instructs to erase the stored information.  <P>COPYRIGHT: (C)2007,JPO&INPIT
The invention relates to a traditional Chinese medicine combination for treating fracture, hairline fracture and traumatic injury. The combination is prepared from internal and external medicines. The bulk pharmaceutical chemicals of the internal medicines comprise nux vomica, Chinese angelica, szechuan lovage rhizome, notoginseng, common club moss herb, rhizoma drynariae, himalayan teasel root, salvia miltiorrhiza, rhizoma corydalis and madder. The bulk pharmaceutical chemicals of the external medicines comprises dragon's blood, realgar, red flower, catecholamine, cinnabar, frankincense, myrrh, Chinese angelica root, paris polyphylla, borneol and musk. The external medicines of the invention have an effect of reducing swelling, and the internal medicines thereof have the effects of tonifying kidney and dredging collaterals, promoting reunion of fractured tendons and bones, and strengthening the therapeutic effect. The traditional Chinese medicine combination for treating fracture, hairline fracture and traumatic injury provided by the invention has the advantages of reasonable combination, fast quick effect taking, high cure rate and no toxic side effect, and is suitable for the treatment of various fracture, hairline fracture and traumatic injury. Soft tissue injury, flesh bruises caused by traumatic injury and back bruises can be cured by internal or external taking, while the fracture, comminuted fracture or broken bone dislocation can be effectively treated by internal and external taking. Therefore, good therapeutic effect is provided for comminuted fracture or broken bone dislocation not being cured for a long time after surgeries in the hospital.
Overweight and obesity are defined as abnormal or excessive fat accumulation that may impair health. Obesity is a substantial public health problem throughout the world, with the prevalence increasing rapidly in numerous developing and developed nations. In 2014, about 13% of the world's adult populations were obese and 39% were overweight. The worldwide prevalence of obesity has more than doubled in over 30 years (WHO, 2016). Obesity and overweight pose major risks for serious diseases, such as dyslipidemia, type 2 diabetes, hypertension, coronary heart disease and stroke (Haslam \& James 2005) and average life expectancy is reduced in obese people (Fontaine et al. 2003). Dietary fat plays a major role in the development of overeating and obesity (Bray et al. 2004); thus fat uptake should be a main target to reduce energy intake and achieve a loss of body weight (Svendsen \& Tonstad, 2011). It has been shown that nutrients such as protein and fibre reduce lipid absorption (e.g. Chong et al., 2014; Hosomi et al., 2010; Tsujita et al., 2007). The main components of the IQP-AE-103 are okra (Abelmoschus esculentus (L.) Moench) pod powder and inulin. Okra pod powder contains a combination of dietary fibre and protein, which may have an important role in fat binding (Kumar et al., 2013). Dehydrated powder derived from okra pod has further been shown to have substantial swelling capabilities when added to water (Bakre \& Jaiyeaob, 2009), which can potentially provide satiety effects. Inulin is a fermentable fructan, derived from plants such as asparagus, garlic, leak, onion etc.

and serves as an important source of soluble dietary fibre (Jaundzeikare and Beitane, 2014), to further enhance the effect of fat binding. The efficacy of IQP-AE-103 in body weight reduction during intake of 12 weeks has been shown recently in a clinical trial with 108 overweight and moderately obese subjects (Uebelhack et al., 2019). The present study aims at a broader evaluation of the beneficial effects of IQP-AE-103 for use in weight management, including its impact on waist circumference, blood pressure and blood glucose and lipid levels as well as quality of life, in overweight and moderately obese subjects.
A system and a method for obtaining a solid form cannabis extracts are disclosed. The method comprises providing a raw biomass material containing a quantity of target compounds for extraction. The raw biomass material may be decarboxylated, ground or pulverized to obtain a prepared cannabis biomass. A slurry may be prepared by adding a solvent to the prepared cannabis biomass. The target components may be extracted from the slurry by processing in a continuous flow extractor. The solvent may be separated from a spent biomass; further, the solvent may be separated from the target components by heating and evaporating the solvent. Successively, the target components may be solidified by a downstream process, such as concentration, separation, isolation, and formulation. In a preferred embodiment, the extract may fully or partially stripped of a solvent and mixed with an excipient before a spray drying process.
B cell-activating factor (BAFF) is a critical TNF-family cytokine that regulates homeostasis and peripheral tolerance of B2 cells. BAFF overproduction promotes autoantibody generation and autoimmune diseases. During obesity, BAFF is predominantly produced by white adipose tissue (WAT), and IgG autoantibodies against adipocytes are identified in the WAT of obese humans. However, it remains to be determined if the autoantibodies formed during obesity affect WAT remodeling and systemic insulin resistance. Here, we show that IgG autoantibodies are generated in high-fat diet (HFD)-induced obese mice that bind to apoptotic adipocytes and promote their phagocytosis by macrophages. Next, using murine models of obesity in which the gonadal WAT undergoes remodeling, we found that BAFF neutralization depleted IgG autoantibodies, increased the number of dead adipocytes, and exacerbated WAT inflammation and insulin resistance. RNA sequencing of the stromal vascular fraction from the WAT revealed decreased expression of immunoglobulin light-chain and heavy-chain variable genes suggesting a decreased repertoire of B cells after BAFF neutralization. Further, the B cell activation and the phagocytosis pathways were impaired in the WAT of BAFF-neutralized mice. In vitro, plasma IgG fractions from BAFF-neutralized mice reduced the phagocytic clearance of apoptotic adipocytes. Altogether, our study suggests that IgG autoantibodies developed during obesity, at least in part, dampens exacerbated WAT inflammation and systemic insulin resistance.
The intervention will be provided by 2 psychotherapists. The total of sessions will be eight carried out weekly, for 2 to 3 months. They will also receive standard treatment, i.e. psychiatric management with or without drugs.
The purpose of the study is to determine if preoperative dosing of darifenacin will assist in postoperative ureteral stent pain. This will be a randomized two arm prospective study to evaluate postoperative ureteral stent pain. One arm will be given 3 days of preoperative darifenacin and the control group will have the standard of care which is no preoperative anticholinergic medication. The primary endpoints will be decreased pain scores and less ER visits and hospital admissions for stent difficulty. These will be assessed by a pain diary completed by the participant as well as a questionnaire when the participant returns to clinic for stent removal. Also included in evaluation of the primary end point will be patient phone calls, ER visits and admissions for stent difficulty. Secondary endpoints will be narcotic and postoperative anticholinergic use. This will also be assessed with the pain diary completed by the participant. Participants will be included in the study if they are undergoing a procedure that a stent will likely be required. This will include participants who will have ureteroscopy or extracorporeal shock wave lithotripsy and a stone 1 cm or larger. Also participants with stones smaller than 1 cm who due to anatomy of the ureter or kidney will likely need a stent on preoperative evaluation will also be included in the study. Included as well in the study are participants who will undergo renal or ureteral surgery that a ureteral stent will be utilized. Participants will be randomized after consent is obtained into two groups. One group will receive standard of care which is no preoperative anticholinegic medications. The second group will receive the three day treatment with darifenacin pre procedure. Participants in the second group will be instructed on side effects of darifenacin and given appropriate contact information prior to initiation of the medication. Both groups will be followed postoperatively with a pain diary. Postoperative follow up will continue until the stent is removed 1-2 weeks after the procedure. The exact time of stent removal will depend on the success and nature of the surgery and will be at the discretion of the surgeon. Participants will be able to voluntarily stop the medication for any reason as well as if they have serious side effects from the medication. Data to be collected from each group includes age, gender, race, prior ureteral stents, prior renal or ureteral surgery, past medical history, allergies, current medications and urinary complaints.
The low-carbohydrate diet will consist of a meal plan of less than 20 grams of carbohydrates per day to be consumed over 6 weeks. Foods that provide high levels of healthy fats (preferably low in saturated fats) will be generously included in the diet plan. Various lean meats, fish, and nutrient rich foods that meet the requirement of less than 20 grams total carbohydrates per day will be included in the meal plans. Carbohydrates will be expected to make up less than 10% of total caloric intake. Participants in the low-carbohydrate diet group will receive a supply of extra virgin olive oil at study visits to incorporate into their individualized meal plans.
AIMS: Excessive opiate analgesia in relation to orthopaedic surgery is associated with morbidity and mortality. Pre-operative use of opiates is associated with higher post-operative use. There is little information about opiate prescribing practices in relation to elective total joint arthroplasty (TJA) in New Zealand rural centres. The aims of this study were to describe opiate use before, immediately after and 1 year after TJA, and to compare prescribing practices with local guidelines.
METHODS: A retrospective cohort study of elective primary hip and knee arthroplasties was conducted between January 2018 and April 2019. Opiate use was evaluated from clinical records and from electronic prescribing records and described in morphine milligram equivalents (MME) with a particular focus on pre-operative and post-operative periods, and use after 1 year.
RESULTS: In the study period, 199 patients underwent 203 joint arthroplasties. Of these, data from 157 patients were analysed. Patient data were not analysed because of unavailable files (N=20), non-elective procedures (N=11), bilateral arthroplasties (N=4), deaths (N=4) and incomplete information (N=3). Pre-operative opiates were used by 92 (59%) patients, of whom 70 (76%) were not using opiates after 1 year. There were 126 (80%) patients who were discharged with opiate prescriptions and the vast majority, 121 (96%), did not receive discharge prescriptions that conformed to local guidelines.
CONCLUSION: Despite undergoing joint arthroplasty, about one quarter of patients who had been prescribed opiates before the operation were still receiving opiates after 1 year. There was poor compliance with local guidelines.
FIELD: medicine. ^ SUBSTANCE: method involves polychemotherapy followed by radiation therapy (RT) with underlying plant-based mouth rinsing and oral administration of Colegel with Derinat and Lidocaine 3 times a day and more often. The polychemotherapy is performed by no more than 2 courses with the radiation started not earlier than in 10-15 days after the polychemotherapy to total basic dose 66-70 Gy and with peripheral blood of an exposed patient analysed for lymphocyte count once in 10 days and more often. If lymphocyte count is 1.2ù109/l or less, the following RT sessions are carried out with underlying additional intensive local and system therapy, or the therapy is interrupted for the hemostimulation therapy. ^ EFFECT: use of the invention allows preventing severity gain in a radiation involvement of oropharyngeal mucosa due to well-timed intensification of local and system therapy, performing a radical RT course and improving clinical effectiveness. ^ 2 cl, 2 ex
The invention discloses application of polygala total saponins in resisting aging and regulating immunity. The polygala tenuifolia saponin can be used for preparing anti-aging products or products for enhancing the immune function. The anti-aging effect research of the invention shows that compared with a model group, the polygala total saponin is high, the thymus index and the spleen index of a medium-dose group are both obviously reduced, and the CAT activity of serum is extremely obviously increased; the SOD activity of the low-dose group is obviously improved. The difference between the MDA level of the brain tissue and the SOD activity of the high, medium and low dose groups has statistical significance. Compared with the model group, the difference between the MDA content of the brain tissue and the SOD activity of the high, medium and low dose groups has statistical significance. The research on the immune function regulation effect shows that compared with a model group, the polygala tenuifolia saponin high-dosage and medium-dosage groups remarkably increase spleen index and thymus index; the high dose group had significantly elevated levels of both serum cytokines IL-2 and IL-6.
PURPOSE:To obtain the subject new antibiotics for medicines and germicides, etc., for agriculture and horticulture, having activity capable of controlling bacteria and plant pathogenic fungi by culturing an antibiotic AB 4063s-producing bacterium belonging to the genus Phoma in a culture medium and then collecting a product from the cultured mixture. CONSTITUTION:An antibiotic AB4063-A and B-producing bacterium belonging to the genus Phoma [e.g. Phoma sp. AB4063 (FERM P-13358)] is inoculated into a culture medium and subjected to rotary shaking culture at 25 deg.C for 5 days using a rotary shaker, and then, the cultured mixture is filtered to collect the yeast cells. Then, acetone is added to the yeast cells and the cells are extracted with acetone at 55-60 deg.C for 30min and the extract is filtered to remove the yeast cells and the yeast extraction liquid is collected and concentrated under reduced pressure. Ethyl acetate is added to the residue and the residue is extracted and fractionated and the extracted liquid is concentrated under reduced pressure and the resultant brown oily substance is purified by a silica get column chromatography to provide the objective new antibiotics AB4063-A and -B expressed by formula I (R is formula II in the case of AB4063-A and formula III in the case of AB4063-B) or their salts.
Macrophage activation syndrome (MAS) is a life-threatening systemic hyperinflammatory syndrome triggered by various infections, particularly viral infections, autoimmune disorders, and malignancy. The condition is characterized by an increased production of proinflammatory cytokines resulting in a cytokine storm and has been associated with poor clinical outcomes. During the COVID-19 pandemic, patients with severe manifestations developed features similar to those of MAS, although these characteristics remained well defined within the lung. Additionally, other viral infections including EBV, the herpes family of viruses, hepatitis viruses, influenza, HIV, and hemorrhagic fevers can be complicated by MAS. The diagnosis and management of the condition remain challenging due to the lack of consensus on specific guidelines, especially among the adult population. Currently, therapeutic options primarily rely on medications that are typically used to treat primary hemophagocytic lymphohistiocytosis, such as corticosteroids and etoposide. In addition, cytokine-targeted therapies present promising treatment options. The objective of this review is to discuss the emergence of MAS in the context of viral infections including, but not limited to, its occurrence in COVID-19.
Textbooks and expert opinion recommend both diazepam and lorazepam as initial therapy for children in status epilepticus (SE) and provide recommended doses that are commonly used. However, unlike diazepam, lorazepam is only FDA-approved for treatment for SE in patients over 18 years of age. Despite this fact, many experts support the use of lorazepam over diazepam in pediatric SE. Increased duration of action, increased effectiveness in terminating SE, and a lower incidence of respiratory depression have been cited as potential advantages of lorazepam over diazepam. However, data to support firm recommendations for one medication over another are lacking. Thus, either diazepam (FDA-approved) or lorazepam can be considered first-line agents for pediatric SE, and the physician's choice of agent depends on local practice patterns and individual treatment styles. In the prehospital (Emergency Medical Services) setting, diazepam is commonly chosen because of a longer shelf life without refrigeration.

The purpose of this study is to determine the differences in efficacy and safety between these two commonly used benzodiazepines, as requested by the FDA under the Best Pharmaceuticals for Children Act, using the Exception from Informed Consent provided by the FDA.